Marshall Edwards, Inc.' Phenoxodiol and Novogen Limiteds NV-128 Display Divergent Mechanisms of Action but Potent Synergistic Anti-Cancer Activity When Used in Combination

NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - October 30, 2008) - Pre-clinical studies presented at the 9th International Conference on Membrane Redox Systems in Wellington New Zealand this week demonstrate that Novogen's NV-128 (a novel mTOR inhibitor), when used in combination with the Marshall Edwards, Inc.'s Phase III anti-ovarian cancer drug, phenoxodiol, produces potent synergistic anti-cancer activity against non-small cell lung carcinoma cell lines (NSCLC). Importantly, the synergistic cytotoxicity observed between NV-128 and phenoxodiol was superior to the synergy observed between NV-128 and paclitaxel against NSCLC. These data were presented by Dr. David Brown, Program Manager (Cancer Biology), Novogen.